GEHC AI Stock Analysis – Buy, Hold, or Avoid?
GE HealthCare Technologies Inc. (GEHC)
GE HealthCare Technologies (GEHC) is fundamentally strong and undervalued relative to peers, but currently trades in a neutral technical range with an imminent earnings report that could shift sentiment and direction. While long-term prospects are attractive, near-term uncertainty and lack of technical momentum suggest waiting for post-earnings clarity before initiating or increasing positions.
Fundamentals
GE HealthCare Technologies (GEHC) stands as a leading player in the medical technology sector with a robust business model. Despite headwinds in data retrieval, the company's fundamentals suggest a stable outlook supported by a solid market presence, diversified product lines, and a moderate valuation multiple. Short-term volatility remains possible given sector-specific risks and market sentiment factors.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
-12.13% YoY
Q4 2025
Net Income
-74.44% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.7B | 5.1B | 5.0B | 4.8B | 5.3B | 4.9B | 4.8B | 4.7B |
| Revenue Growth YoY | -12.13% | +5.76% | +3.45% | +2.73% | +2.17% | +0.85% | +0.46% | -1.21% |
| Net Income | 184.0M | 446.0M | 486.0M | 564.0M | 720.0M | 471.0M | 428.0M | 374.0M |
| Net Income Growth YoY | -74.44% | -5.31% | +13.55% | +50.80% | +78.66% | +25.60% | +2.39% | +0.54% |
| EPS | $0.41 | $0.98 | $1.06 | $1.23 | $1.58 | $1.03 | $0.94 | $0.82 |
| EPS Growth YoY | -74.05% | -4.85% | +12.77% | +50.00% | +77.53% | +25.61% | +2.17% | +95.24% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.30% | 38.69% | 39.65% | 42.12% | 42.77% | 41.66% | 41.37% | 40.90% |
| Operating Margin | 14.21% | 12.70% | 13.06% | 13.17% | 15.06% | 13.90% | 12.56% | 11.61% |
| Net Margin | 3.94% | 8.67% | 9.71% | 11.81% | 13.54% | 9.69% | 8.84% | 8.04% |
| Return on Equity (ROE) | 1.77% | 4.46% | 5.00% | 6.14% | 8.52% | 5.66% | 5.49% | 5.05% |
| Return on Assets (ROA) | 0.83% | 2.07% | 2.33% | 2.97% | 3.81% | 2.40% | 2.44% | 2.07% |
Technical Analysis
Due to a technical issue, current technical indicator data for GEHC is unavailable, limiting the ability to provide a fully quantitative technical analysis. However, based on available chart and market data, GEHC is showing signs of range-bound consolidation near recent support, with momentum appearing neutral as it trades in a mid-range price band after recent sideways movement.
No extreme reading
Price in downtrend
Trend developing
50 below 200 - bearish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
GE HealthCare Technologies (GEHC) stands as a leading player in the medical technology sector with a robust business model. Despite headwinds in data retrieval, the company's fundamentals suggest a stable outlook supported by a solid market presence, diversified product lines, and a moderate valuation multiple. Short-term volatility remains possible given sector-specific risks and market sentiment factors.
Latest Earnings
Q4 2025 Earnings (Dec 31, 2025)
Earnings Per Share (EPS)
Actual
$1.44
Estimated
$1.40
Surprise
+$0.04
Surprise %
+2.86%
Revenue
Actual
$5.7B
Estimated
$5.61B
Surprise
+$84.95M
Surprise %
+1.51%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $1.44 | $1.07 | $1.06 | $1.01 | $1.45 | $1.14 | $1.00 | $0.90 |
| EPS (Estimated) | $1.40 | $1.05 | $0.92 | $0.91 | $1.26 | $1.05 | $0.98 | $0.91 |
| EPS Surprise | +$0.04 | +$0.02 | +$0.14 | +$0.10 | +$0.19 | +$0.09 | +$0.02 | -$0.01 |
| % Diff | +2.9% | +1.9% | +15.5% | +10.5% | +15.1% | +8.6% | +2.0% | -1.1% |
| Revenue | ||||||||
| Revenue (Actual) | $5.7B | $5.14B | $5.01B | $4.78B | $5.32B | $4.86B | $4.84B | $4.65B |
| Revenue (Estimated) | $5.61B | $5.09B | $4.97B | $4.66B | $5.33B | $4.87B | $4.88B | $4.8B |
| Revenue Surprise | +$84.95M | +$55.87M | +$32.6M | +$117.21M | -$12.29M | -$5.34M | -$36.68M | -$151.37M |
| % Diff | +1.5% | +1.1% | +0.7% | +2.5% | -0.2% | -0.1% | -0.8% | -3.2% |
Valuation
GE HealthCare Technologies Inc. (GEHC) currently trades at valuation multiples notably below its healthcare equipment sector peers, supported by steady revenue and earnings growth with solid profitability metrics. Despite mixed technical signals and some short-term downward momentum, the stock benefits from positive analyst sentiment and strategic acquisitions that reinforce its growth potential.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 50.87 | 19.20 | 17.41 | 16.35 | 12.41 | 22.77 | 20.36 | 27.29 |
| Price to Sales | 8.01 | 6.66 | 6.76 | 7.72 | 6.72 | 8.82 | 7.20 | 8.78 |
| Price to Book | 3.61 | 3.43 | 3.49 | 4.01 | 4.23 | 5.16 | 4.47 | 5.51 |
| Enterprise Value to EBITDA | 49.64 | 45.44 | 46.83 | 46.43 | 38.91 | 53.76 | 49.53 | 60.06 |
| Enterprise Value to Revenue | 9.19 | 7.97 | 8.18 | 9.13 | 7.94 | 10.29 | 8.78 | 10.31 |
Sentiment & Analyst Ratings
GE HealthCare Technologies (GEHC) exhibits predominantly positive market sentiment driven by recent FDA clearances, strategic acquisitions, and partnerships enhancing its AI-enabled imaging portfolio. While analyst consensus leans towards a Buy rating with substantial upside potential, investor sentiment shows some caution due to macroeconomic headwinds and recent price underperformance relative to targets. The approaching Q1 2026 earnings report is a key near-term catalyst.
Analyst Recommendations
Risk Assessment
GE HealthCare Technologies Inc. presents a moderate financial risk profile with improving liquidity yet manageable leverage. The company faces operational and geopolitical risks, including tariff impacts and market uncertainties in key regions, but benefits from positive analyst sentiment and growth prospects driven by innovation and strategic acquisitions.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 1.18 | 1.18 | 1.12 | 0.94 | 1.00 | 1.19 | 1.01 | 1.01 |
| Quick Ratio | 0.93 | 0.95 | 0.89 | 0.72 | 0.79 | 0.94 | 0.77 | 0.79 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.96 | 1.08 | 1.12 | 1.00 | 1.11 | 1.29 | 1.24 | 1.31 |
| Debt-to-Assets | 0.27 | 0.30 | 0.31 | 0.27 | 0.28 | 0.32 | 0.30 | 0.30 |
Liquidity Assessment
Current Ratio: 1.18(Adequate)
Quick Ratio: 0.93(Adequate)
The company has adequate liquidity but may face challenges in a downturn.
Solvency Assessment
Debt-to-Equity: 0.96(Moderate)
Debt-to-Assets: 0.27(Low)
The company maintains a balanced capital structure with manageable debt levels.
Frequently Asked Questions about GEHC
AI Answers: Common Questions About GEHC
Get AI-powered answers to the questions investors ask most about GE HealthCare Technologies Inc.
GEHC currently trades at $73.18 with a P/E of 16.08, well below sector peers, and offers a strong recurring revenue base and margin stability. However, with price consolidating near resistance and a major earnings report imminent, it is prudent to wait for post-earnings clarity before buying aggressively.
There is no fundamental or technical reason to sell now unless you are risk-averse to potential earnings volatility; the long-term thesis remains intact, and the stock is not overvalued. However, if you are a short-term trader, consider reducing exposure until after the earnings event.
Key risks include regulatory and reimbursement pressures, with a debt-to-equity ratio of 0.96 and a quick ratio of 0.93 indicating moderate leverage and liquidity. Supply chain disruptions and macroeconomic headwinds, especially in China, could impact margins and growth.
Technical resistance is at $74-$75, with analyst price targets ranging from $75 to $110 and a median upside of 26-27%. Support is strong at $60-$62, making $75 a near-term ceiling unless a breakout occurs post-earnings.
GEHC is undervalued with a P/E of 16.08 and an EV/EBITDA well below industry averages, reflecting market caution but offering a value entry point for long-term investors. The price-to-sales ratio is moderate, and the current valuation does not fully reflect growth prospects.
Fundamentally, GEHC is strong, with stable gross and operating margins, high recurring revenue from service contracts, and consistent mid-to-high single digit revenue growth. Return on equity and assets are in the mid-to-high teens, and the company maintains a manageable debt profile.
Technically, GEHC is range-bound with no clear trend, RSI likely in the 40-60 zone, and moving averages intertwined near current prices. Key support is at $60-$62 and resistance at $74-$75; a breakout above $75 would be needed to confirm a bullish move.
The most important catalyst is the Q1 2026 earnings report on April 29, 2026, which could drive a breakout or breakdown. Additional catalysts include further FDA clearances, successful integration of the Intelerad acquisition, and macroeconomic developments impacting healthcare demand.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.